Search

Our goal of transforming the treatment of neuroendocrine carcinomas

Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).

Positive-CHMP-opinion-for-dabigatran-in-children

Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children

emperor-reduced-chmp-positive-opinion

CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction

Geographic Atrophy treatment to move to Phase II

Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results

U.S. FDA grants priority review for spesolimab in GPP

U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis

L'Arte di Respirare IN IPF

Expert Prof. Richeldi discusses the link between Idiopathic Pulmonary Fibrosis (IPF) and Leonardo da Vinci and importance of taking action early.

Interview with Michael Schmelmer

"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors

TreatmentSequencing

How can we improve blood pressure control?

Interview with Professor Michael Böhm, University of the Saarland, Homburg/Saar, Germany

GARC Louis Nel interview on global rabies control

GARC’s Executive Director Professor Louis Nel shares what it takes to fight rabies.

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

EU approved Jardiance for type 2 diabetes in children

Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above

European Commission decision for Pradaxa® in children with VTE

Pradaxa® (dabigatran etexilate) receives EU marketing authorization for the treatment and prevention of VTE in children from birth to less than 18 years of age

European_Commission_approves_nintedanibSSc-ILD

Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease

cat feline diabetes medication treatment fda approval

Boehringer Ingelheim receives FDA approval for SENVELGO®

Saving Lives

The Angels initiative honours nurses saving lives one grandpa at a time

NEJM-IL-36-Phase-1-GPP-data

Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis

Partnership-with-clicktherapeutics

Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia

Boehringer founding sponsor of CKM Health Initiative

Boehringer Ingelheim founding sponsor of AHA's Cardiovascular-Kidney-Metabolic Health Initiative

Improving Access to Stroke Care

Angels Initiative named Best Practice example by the Access to Medicine Index

Fast-Track-Designation-NASH

Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.

FDA-Fast-Track-chronic-kidney-disease

FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition

collaboration-LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders

Veterinary oncology - cancer treatment

Our R&D team's efforts toward finding new cancer treatments for pets

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers